5-chloro-2(1H)-PYRIMIDONE hydrochloride | 42748-90-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-chloro-2(1H)-PYRIMIDONE hydrochloride
• 英文别名: 5-chloro-2(1H)-pyrimidinone hydrochloride；chloropyrimidin-2(1H)one hydrochloride；5-chloropyrimidin-2-one hydrochloride；5-Chloropyrimidin-2-ol hydrochloride；5-chloro-1H-pyrimidin-2-one;hydrochloride
• CAS: 42748-90-3
• 化学式: C₄H₃ClN₂O*ClH
• mdl: MFCD09250871
• 分子量: 166.995
• InChiKey: GRLWQORZOWPFCM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.03
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.5
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温下密封保存，并确保环境干燥。

反应信息

• 作为反应物：
  描述：

  5-chloro-2(1H)-PYRIMIDONE hydrochloride 在 crude product 作用下， 以 三氯氧磷 为溶剂， 反应 1.5h， 以to furnish the title compound 20 as a crystalline white solid (273 mg)的产率得到4,5-dichloropyrimidine hydrochloride
  参考文献：
  名称：

  Pyridine and pyrimidine based compounds as Wnt signaling pathway inhibitors for the treatment of cancer

  摘要：

  本发明涉及以吡啶和嘧啶为基础的化合物、包含这些化合物的药物组合物以及它们作为治疗和/或预防癌症的潜在治疗剂的用途。

  公开号：

  US08778925B2

文献信息

• [EN] PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS À BASE DE PYRIDINE ET DE PYRIMIDINE EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION WNT POUR LE TRAITEMENT DU CANCER
  申请人：CANCER REC TECH LTD

  公开号：WO2010041054A1

  公开（公告）日：2010-04-15

  The present invention relates to pyridine and pyrimidine based compounds, pharmaceutical compositions comprising these compounds and their potential use as therapeutic agents for the treatment and / or prevention of cancer.

  本发明涉及以吡啶和嘧啶为基础的化合物，包括这些化合物的药物组合物，以及它们作为治疗和/或预防癌症的潜在用途。
• Substituted pyrimidin-2-ones, the salts thereof, processes for their
  申请人：Glaxo Group Limited

  公开号：US04636509A1

  公开（公告）日：1987-01-13

  Compounds of the general formula: ##STR1## (wherein X represents a halogen atom or a trifluoromethyl group; R.sup.1 represents an optionally substituted C.sub.6-10 carbocyclic aromatic group; and R.sup.2 represents a hydrogen atom or a lower alkyl, C.sub.7-16 aralkyl or C.sub.6-10 aryl group or the group COR.sup.1a, in which R.sup.1a is as defined for R.sup.1, R.sup.1 and R.sup.1a being the same or different) and where an acidic or basic group is present, the salts thereof have been found to possess excellent metaphase arresting ability and are of use in combating abnormal cell proliferation. Thus a knowledge of the cell division cycles of the normal and abnormal cells enables a cytotoxic drug to be administered while the abnormal cells are in a phase susceptible to attack and while the normal cells are in a non-susceptible phase. The compounds of the invention are prepared by alkylation, deprotection of a protected keto group, oxidation or electrophilic halogenation. Pharmaceutical compositions containing the compounds of formula I, and where appropriate, the physiologically compatible salts thereof; and methods for the use of the compounds are described and claimed.

  通式为：##STR1##（其中X代表卤原子或三氟甲基基团；R.sup.1代表可选择取代的C.sub.6-10碳环芳基团；R.sup.2代表氢原子或较低的烷基、C.sub.7-16芳基烷基或C.sub.6-10芳基团或基团COR.sup.1a，其中R.sup.1a如R.sup.1所定义，R.sup.1和R.sup.1a相同或不同）并且存在酸性或碱性基团，已发现其盐具有出色的中期阻滞能力，并可用于对抗异常细胞增殖。因此，了解正常和异常细胞的细胞分裂周期使得可以在异常细胞处于易受攻击阶段而正常细胞处于不易受攻击阶段时给予细胞毒性药物。本发明的化合物通过烷基化、去保护受保护的酮基团、氧化或亲电卤代反应制备。描述和声明了含有通式I化合物的药物组合物，以及在适当情况下其生理相容盐；并描述和声明了使用这些化合物的方法。
• Substituted pyrimidin-2-ones and the salts thereof
  申请人：Nyegaard & Co. A.S.

  公开号：US04596870A1

  公开（公告）日：1986-06-24

  Compounds of the general formula: ##STR1## (wherein X represents a halogen atom or a trifluoromethyl group; R.sup.1 and R.sup.2 independently represent a hydrogen atom or a lower alkyl group; Z is --O--, --S--, --SO--, --SO.sub.2 -- or the group --NR.sup.4 -- wherein R.sup.4 is as defined for R hereinafter or represents the group COR.sup.5 in which R.sup.5 represents a hydrogen atom or an optionally substituted aryl, heterocyclic, aralkyl, lower alkyl or lower alkoxy group; R represents a C.sub.6-10 carbocyclic aromatic group or a heterocyclic group containing a 5-9 membered unsaturated or aromatic heterocyclic ring which ring contains one or more heteroatoms selected from O, N and S and optionally carries a fused ring which carbocyclic or heterocyclic group may carry one or more C.sub.1-4 alkyl or phenyl groups, said groups being optionally substituted; or, where Z represents the group >NR.sup.4, the group --ZR may represent a heterocyclic ring optionally carrying a fused ring and/or optionally substituted as defined for R; and R.sup.3 represents a hydrogen atom or a lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower alkenoyl, C.sub.7-16 aralkyl or C.sub.6-10 arly group or a 5-9 membered unsaturated or aromatic heterocyclic ring); and, where acid or basic groups are present, the salts thereof; are useful in combating abnormal cell proliferation. The compounds of the invention are prepared by inter alia alkylation, ring closure and oxidation.

  通式为：##STR1## 的化合物（其中X代表卤素原子或三氟甲基基团；R.sup.1和R.sup.2分别代表氢原子或较低的烷基基团；Z为--O--，--S--，--SO--，--SO.sub.2 --或基团--NR.sup.4 --其中R.sup.4如下所定义或代表基团COR.sup.5，其中R.sup.5代表氢原子或可选择取代的芳香族、杂环、芳基烷基、较低的烷基或较低的烷氧基团；R代表C.sub.6-10碳环芳族或含有5-9个成员的不饱和或芳香杂环环，该环含有O、N和S中选定的一个或多个杂原子，并且可选择携带一个融合环的碳环或杂环基团，该碳环或杂环基团可以携带一个或多个C.sub.1-4烷基或苯基基团，这些基团可选择取代；或者，Z代表基团>NR.sup.4时，基团--ZR可以代表一个可选择携带一个融合环和/或可选择取代的杂环环，如R所定义；R.sup.3代表氢原子或较低的烷基、较低的烯基、较低的炔基、较低的烷酰基、较低的烯酰基、C.sub.7-16芳基烷基或C.sub.6-10芳基基团或一个5-9成员的不饱和或芳香杂环环）；并且，如有酸性或碱性基团存在，其盐；在对抗异常细胞增殖方面是有用的。该发明的化合物是通过烷基化、环闭合和氧化等方法制备的。
• 5-Halo-pyrimidin-2-ones, the salts thereof
  申请人：Nyegaard & Co. A/S

  公开号：US04399140A1

  公开（公告）日：1983-08-16

  Compounds of the formula: ##STR1## wherein X represents a halogen atom; R.sup.1 and R.sup.2, which may be same or different, each represents a hydrogen atom, or a C.sub.1-4 alkyl group; Het represents a C-attached 3-9 membered, saturated, unsaturated or aromatic heterocyclic ring containing one or more hetero atoms selected from O, N and S and optionally carrying a fused ring and/or optionally substituted by one or more substituents selected from halogen atoms and hydroxy, C.sub.1-4 alkoxy, amino, acylamino, nitro, oxo, C.sub.1-4 alkyl groups and monocyclic carbocyclic and heterocyclic aryl groups having 5 to 8 ring members; such a heterocyclic ring being saturated and having only a single heteroatom when there are 3 or 4 ring members; and alk represents a C.sub.1-4 saturated or unsaturated, straight or branched chain, divalent aliphatic hydrocarbyl group optionally substituted by one or more groups selected from carbocyclic aryl groups and heterocyclic groups as defined for Het above, and the salts thereof have been found to possess metaphase arresting ability which by virtue of its reversibility is of use in combating abnormal cell proliferation. Thus a knowledge of the cell division cycles of the normal and abnormal cells enables a cytotoxic drug to be administered while the abnormal cells are in a phase susceptible to attack and while the normal cells are in a non-susceptible phase. The compounds of the invention are prepared by alkylation, ring closure of the pyrimidine ring, halogenation or ring closure of the heterocyclic ring Het.

  式为：##STR1## 其中 X 代表卤原子；R.sup.1 和 R.sup.2，可能相同也可能不同，每个代表氢原子，或者 C.sub.1-4 烷基基团；Het 代表一个连接到 C 的 3-9 个成员的饱和、不饱和或芳香杂环环，其中包含一个或多个来自 O、N 和 S 的杂原子，并且可能携带一个融合环和/或可选择地被一个或多个来自卤原子和羟基、C.sub.1-4 烷氧基、氨基、酰胺基、硝基、氧代基、C.sub.1-4 烷基基团和含有 5 到 8 个环成员的单环碳环和杂环芳基团取代的取代基；当有 3 或 4 个环成员时，这样的杂环环是饱和的，并且只有一个杂原子；alk 代表一个 C.sub.1-4 饱和或不饱和的、直链或支链、双价脂肪烃基团，可选择地被一个或多个来自碳环芳基团和如上所述的 Het 的杂环基团的取代基取代，以及其盐已被发现具有相位阻滞能力，由于其可逆性，可用于对抗异常细胞增殖。因此，对正常和异常细胞的细胞分裂周期的了解使得细胞毒性药物可以在异常细胞处于易受攻击阶段而正常细胞处于非易受攻击阶段时进行给药。本发明的化合物通过烷基化、嘧啶环的环闭合、卤化或杂环环 Het 的环闭合制备。
• Substituted pyrimidin-2-ones, the salts thereof, pharmaceutical
  申请人：Glaxo Group Limited

  公开号：US04650800A1

  公开（公告）日：1987-03-17

  Compounds of the general formula: ##STR1## wherein X represents a halogen atom or a trifluoromethyl group; R.sup.1 represents a hydrogen atom or a lower alkyl group and Het represents an optionally substituted C-attached 5-7 membered aromatic heterocyclic ring which ring contains one or more heteroatoms selected from O, N and S and optionally carries a fused ring and where an acidic or basic group is present, the salts thereof have been found to possess excellent metaphase arresting ability and are of use in combating abnormal cell proliferation. Thus a knowledge of the cell division cycles of the normal and abnormal cells enables a cytotoxic drug to be administered while the abnormal cells are in a phase susceptible to attack and while the normal cells are in a non-susceptible phase. The compounds of the invention are prepared by alkylation, deprotection of a protected keto group, oxidation or electrophilic halogenation.

  通式化合物：##STR1##其中X代表卤素原子或三氟甲基；R1代表氢原子或低级烷基，Het代表可选择性取代的C连接的5-7元芳香杂环，该环含有一个或多个选自O、N和S的杂原子，并可选择性地带有融合环，且当存在酸性或碱性基团时，其盐已被发现具有优异的染色体中期阻滞能力，并可用于对抗异常细胞增殖。因此，了解正常和异常细胞的分裂周期使得可以在异常细胞处于易受攻击阶段时给予细胞毒性药物，而正常细胞处于非易受攻击阶段。本发明的化合物通过烷基化、保护酮基的去保护、氧化或亲电卤化制备。